Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 31:11:2093.
doi: 10.3389/fimmu.2020.02093. eCollection 2020.

Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN

Jonas Samuel Jutzi  1 , Ann Mullally  1   2   3
Affiliations
Review

Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN

Jonas Samuel Jutzi et al. Front Immunol. .

Abstract

Philadelphia-negative myeloproliferative neoplasms (MPN) are malignant bone marrow (BM) disorders, typically arising from a single somatically mutated hematopoietic stem cell. The most commonly mutated genes, JAK2, CALR, and MPL lead to constitutively active JAK-STAT signaling. Common clinical features include myeloproliferation, splenomegaly and constitutional symptoms. This review covers the contributions of cellular components of MPN pathology (e.g., monocytes, megakaryocytes, and mesenchymal stromal cells) as well as cytokines and soluble mediators to the development of myelofibrosis (MF) and highlights recent therapeutic advances. These findings outline the importance of malignant and non-malignant BM constituents to the pathogenesis and treatment of MF.

Keywords: CALR; JAK2; MPL; MPN; inflammation; megakaryocytes; mesenchymal stromal cells; monocytes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Csh Perspect Med. (2019) 10:a034876. 10.1101/cshperspect.a034876 - DOI - PMC - PubMed
    1. Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. (2017) 129:1607–16. 10.1182/blood-2016-10-696005 - DOI - PMC - PubMed
    1. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. (2013) 13:285–99. 10.1016/j.stem.2013.06.009 - DOI - PMC - PubMed
    1. Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. (2008) 112:3065–72. 10.1182/blood-2008-03-143537 - DOI - PubMed
    1. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. (2020) 7:e196–208. 10.1016/s2352-3026(19)30236-4 - DOI - PubMed

Publication types

MeSH terms

Substances